Isotopia Molecular Imaging
Modiin, Israel· Est.
Global leader in GMP‑grade radiopharmaceuticals and theranostic services for cancer diagnosis and therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Global leader in GMP‑grade radiopharmaceuticals and theranostic services for cancer diagnosis and therapy.
OncologyDiagnostics
Technology Platform
GMP‑grade isotope production and aseptic manufacturing of radiopharmaceuticals, enabling theranostic PET/SPECT imaging and targeted radionuclide therapy.
Opportunities
Expansion of Tb‑161 theranostics, scaling CMO services for sterile biologics, and broader FDA approvals for Lu‑177‑based therapies.
Risk Factors
High capital requirements for isotope production, regulatory complexity across regions, and competition from larger nuclear‑medicine firms.
Competitive Landscape
Competes with companies such as Novartis (Lutathera), IBA, and Cardinal Health; differentiation lies in integrated GMP‑grade isotope supply, CMO capabilities, and emerging Tb‑161 technology.